Replies to post #250124 on Biotech Values

[DewDiligence]

They won't have to redo any clinical work, as far as I can tell. The T2D and obesity cohorts were handled separately.

[Mufaso]

GPCR-if we look only at the weightloss side, a 4.7% decrease in 8 weeks isn't too bad,IMO.

I agree it's not too bad but it's not great like the market was expecting. Can they compete on tolerability/safety? Maybe. But they need to complete some longer and much larger studies.